CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Duration: October 1, 2009
to
present
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations , Medical/Disease Research/Clinical Labs , Science/Technology
Spending: about $3,590,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: U.S. Senate, House of Representatives, Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Office of Science & Technology Policy (OSTP), Office of Science & Technology Policy (OSTP),, U.S. Senate,, Centers For Medicare and Medicaid Services (CMS),, Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Agency for Health Care Policy & Research, Natl Institutes of Health (NIH),, Natl Institute of Standards & Technology (NIST)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Michael Werner
91-93 Policy Advisor, Senate Democratic Policy Committee
Paul Bock
Chief of Staff, Senator Herb Kohl
Counsel, Senate Judiciary Committee
Kerry Feehery
Staff Asst., Special Asst., Dep. Press Sec., Sen. Connie Mac
Press Secretary, Joint Economic Committee
Policy Analyst, Senate Budget Committee
Communications Director, Sen. Mel Martinez
Director, State Office of Sen. George LeMieux
Chief of Staff, Sen. George LeMieux
Kathryn Lehman
Chief of Staff, House Republican Conference; Director of Coalition Outreach, Speaker of House; Policy Director, House Majority Whip; Special Assistant to Speaker of the House; Chief Counsel, Sbcmte. on Constitution, H. Judiciary Cmte.
Lauri Hettiner
Staff Director, Sen. George Voinovich
Lauri Hettinger
LA, Sen. George Voinovich
LA, Sen. Norm Coleman
Senior Research Analyst, NRSC
LA & Leg. Correspondent, Sen. Strom Thurmund
Lisa Barkovic
01/01-04/05, Legislative Assistant, Rep. Foley
1/01-4/05 Legislative Assistant, Rep. Mark Foley
Ridge Blanchard
Legislative Correspondent, Rep. Jeff Landry
Legislative Aide, Rep. Jeff Landry
Paolo Mastrangelo
01/09-01/11, Legislative Assistant - Rep. Kosmas
LA, Rep. Suzanne M. Kosmas
Sam Tatevosyan
Leg. Correspondent, Senator Wayne Allard
Marissa Serafino
Staff Assistant, Legislative Assistant, Senator Jeanne
Jodi Richardson
Scheduler & Staff Director, Rep. Todd Young
Scheduler & Staff Director, Representative Todd Young
Miranda Franco
n/a
Andrew Conlin
n/a
Peter Omerod
n/a
David Mann
n/a
Lindsay Britt
n/a
Randy Fenninger
n/a
Andrew Scholnick
n/a
Linsay Britt
n/a
Ethan Jorgensen-Earp
n/a
Isabel Lane
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $30,000. The report was filed on April 14.
Original Filing: 301549121.xml
Lobbying Issues
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
4th Quarter, 2023
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $90,000. The report was filed on Jan. 13.
Original Filing: 301524199.xml
Lobbying Issues
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
3rd Quarter, 2023
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $90,000. The report was filed on Oct. 13, 2023.
Original Filing: 301500495.xml
Lobbying Issues
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment; Accelerating Kids Access to Care Act (S. 2372/ HR 4758); MVP Act (HR 2666).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
2nd Quarter, 2023
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $90,000. The report was filed on July 12, 2023.
Original Filing: 301474743.xml
Lobbying Issues
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
1st Quarter, 2023
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $90,000. The report was filed on April 12, 2023.
Original Filing: 301450636.xml
Lobbying Issues
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS policies and federal legislation regarding Value Based payment legislation; Promote policies to support value based payment.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
4th Quarter, 2022
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $90,000. The report was filed on Jan. 18, 2023.
Original Filing: 301429918.xml
Lobbying Issues
CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
3rd Quarter, 2022
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $90,000. The report was filed on Oct. 17, 2022.
Original Filing: 301405106.xml
Lobbying Issues
CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
2nd Quarter, 2022
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on July 8, 2022.
Original Filing: 301378332.xml
Lobbying Issues
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act; H.R. 7389, the Medicaid VBPs for Patients (MVP) Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation; H.R. 7667, Food and Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
1st Quarter, 2022
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on April 16, 2022.
Original Filing: 301357483.xml
Lobbying Issues
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA user fee legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
4th Quarter, 2021
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Jan. 18, 2022.
Original Filing: 301325954.xml
Lobbying Issues
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
3rd Quarter, 2021
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Oct. 16, 2021.
Original Filing: 301300490.xml
Lobbying Issues
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
2nd Quarter, 2021
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on July 7, 2021.
Original Filing: 301273850.xml
Lobbying Issues
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Value Based Payment legislation; Cures 2.0 legislation; CMS policies regarding Value Based legislation; FDA appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
1st Quarter, 2021
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on April 13, 2021.
Original Filing: 301252083.xml
Lobbying Issues
Value Based Payment" draft legislation; Cures 2.0 legislative discussions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Value Based Payment" draft legislation; Cures 2.0 legislative discussions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
4th Quarter, 2020
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Jan. 14, 2021.
Original Filing: 301230912.xml
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; "Value Based Payment" draft legislation; Cures 2.0 legislative discussions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; "Value Based Payment" draft legislation; Cures 2.0 legislative discussions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
3rd Quarter, 2020
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Oct. 12, 2020.
Original Filing: 301208865.xml
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; "Value Based Payment" draft legislation; Cures 2.0 legislative discussions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; "Value Based Payment" draft legislation; Cures 2.0 legislative discussions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
2nd Quarter, 2020
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on July 7, 2020.
Original Filing: 301185702.xml
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; "Value Based Payment" draft legislation; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act.; Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748); Cures 2.0 legislative discussions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; "Value Based Payment" draft legislation; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748); Cures 2.0 legislative discussions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
1st Quarter, 2020
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on April 7, 2020.
Original Filing: 301154363.xml
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; "Value Based Payment" draft legislation; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act.; Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; "Value Based Payment" draft legislation; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act.; Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
4th Quarter, 2019
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Jan. 11, 2020.
Original Filing: 301104527.xml
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; regulatory reimbursement issues; "Value Based Payment" draft legislation; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; regulatory reimbursement issues; "Value Based Payment" draft legislation; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
3rd Quarter, 2019
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Oct. 17, 2019.
Original Filing: 301068249.xml
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; regulatory reimbursement issues; "Value Based Payment" draft legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; regulatory reimbursement issues; "Value Based Payment" draft legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
2nd Quarter, 2019
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on July 5, 2019.
Original Filing: 301043312.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues; "Value Based Payment" draft legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues; "Value Based Payment" draft legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2019
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on April 9, 2019.
Original Filing: 301023660.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues; "Value Based Payment" draft legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues; "Value Based Payment" draft legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2018
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Jan. 15, 2019.
Original Filing: 301004501.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues; value-based arrangements draft legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2018
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Oct. 18, 2018.
Original Filing: 300988150.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2018
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on July 10, 2018.
Original Filing: 300963361.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; H.R. 2430, S. 204, Trickett Wendler Right to Try Act; other FDA and CMS-related issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2018
HOLLAND & KNIGHT LLP amended a lobbying report for representation of Alliance for Regenerative Medicine in Q12018 on April 27, 2018.
Original Filing: 300959341.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; H.R. 2430, S. 204, Trickett Wendler Right to Try Act; other FDA-related issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2018
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on April 2, 2018.
Original Filing: 300942136.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; H.R. 2430, S. 204, Trickett Wendler Right to Try Act; other FDA-related issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
4th Quarter, 2017
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Jan. 17, 2018.
Original Filing: 300925500.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; H.R. 2430, S. 204, Trickett Wendler Right to Try Act; other FDA-related issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2017
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Oct. 9, 2017.
Original Filing: 300902186.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; S.934, the FDA Reauthorization Act of 2017; H.R. 2430, S. 204, Trickett Wendler Right to Try Act; other FDA-related issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
2nd Quarter, 2017
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on July 14, 2017.
Original Filing: 300885067.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions; S.934, the FDA Reauthorization Act of 2017; H.R. 2430, S. 204, Trickett Wendler Right to Try Act; other FDA-related issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2017
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on April 11, 2017.
Original Filing: 300863933.xml
Lobbying Issues
Implementation of 21st Century Cures regenerative medicine provisions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
4th Quarter, 2016
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Jan. 13, 2017.
Original Filing: 300845915.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine; lobbied regarding regenerative medicine provisions in S.2689, The REGROW Act; S.2443 & H.R. 4669, Advancing Standards in Regenerative Medicine Act; Senate Innovation for Healthier Americans; H.R. 34, the 21st Century Cures Act; S.2837, Commerce, Justice, Science and Related Appropriations Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2016
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Oct. 11, 2016.
Original Filing: 300826483.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine; lobbied regarding regenerative medicine provisions in FDA reform legislation; S. 2689, The REGROW Act; S.2443 & H.R. 4669, Advancing Standards in Regenerative Medicine Act; Senate Innovation for Healthier Americans.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
2nd Quarter, 2016
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on July 8, 2016.
Original Filing: 300807686.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine; lobbied regarding regenerative medicine provisions in FDA reform legislation; S. 2689, The REGROW Act; S.2443 & H.R. 4669, Advancing Standards in Regenerative Medicine Act; Senate Innovation for Healthier Americans.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2016
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on April 12, 2016.
Original Filing: 300790034.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine; lobbied regarding regenerative medicine provisions in FDA reform legislation; S. 2689, The REGROW Act; S.2443 & H.R. 4669, Advancing Standards in Regenerative Medicine Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2015
HOLLAND & KNIGHT LLP amended a lobbying report for representation of Alliance for Regenerative Medicine in Q42015 on Feb. 9, 2016.
Original Filing: 300786323.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Also worked with White House on "Grand Challenge." Lobbied for regenerative medicine provisions in H.R. 6, the 21st Century Cures Act and FDA reform legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2015
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Jan. 14, 2016.
Original Filing: 300771782.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Also worked with White House on "Grand Challenge." Lobbied for regenerative medicine provisions in H.R. 6, the 21st Century Cures Act and FDA reform legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2015
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Oct. 2, 2015.
Original Filing: 300750676.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Also worked with White House on "Grand Challenge." Lobbied for regenerative medicine provisions in the "21st Century Cures" and FDA reform legislation. Lobbied for NNMI funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Medicare/Medicaid reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2015
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on July 10, 2015.
Original Filing: 300732989.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Also worked with White House on "Grand Challenge." Lobbied for regenerative medicine provisions in the "21st Century Cures" and FDA reform legislation. Lobbied for NNMI funding. Medicare/Medicaid reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Medicare/Medicaid reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2015
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on April 13, 2015.
Original Filing: 300714484.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Also worked with White House on "Grand Challenge." Lobbied for regenerative medicine provisions in the "21st Century Cures" and FDA reform legislation. Medicare/Medicaid reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2014
HOLLAND & KNIGHT LLP amended a lobbying report for representation of Alliance for Regenerative Medicine in Q42014 on July 30, 2015.
Original Filing: 300748119.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Lobbied in support of H.R. 4494, S.2126, the Representative Medicare Promotion Act of 2014. Also worked with White House on "Grand Challenge." Also lobbied regarding H.R. 4800/S.2389, the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP)
4th Quarter, 2014
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Jan. 9, 2015.
Original Filing: 300693700.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Lobbied in support of H.R. 4494, S.2126, the Representative Medicare Promotion Act of 2014. Also worked with White House on "Grand Challenge." Also lobbied regarding H.R. 4800/S.2389, the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Office of Science & Technology Policy (OSTP),
3rd Quarter, 2014
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $50,000. The report was filed on Oct. 7, 2014.
Original Filing: 300674098.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Lobbied in support of legislation that would establish the national strategy, including a GAO report and federal policy coordination, which became S.2126, the Representative Medicare Promotion Act. Also worked with White House on "Grand Challenge." Also lobbied regarding H.R. 4800/S.2389, the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015. Worked with Medical Technology Caucus to arrange briefing.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Office of Science & Technology Policy (OSTP),
2nd Quarter, 2014
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on July 10, 2014.
Original Filing: 300654869.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Lobbied in support of legislation that would establish the national strategy, including a GAO report and federal policy coordination, which became S.2126, the Representative Medicare Promotion Act. Also worked with White House on "Grand Challenge." Also lobbied regarding H.R. 4800/S.2389, the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Office of Science & Technology Policy (OSTP),
1st Quarter, 2014
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on April 11, 2014.
Original Filing: 300634592.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Lobbied in support of legislation that would establish the national strategy, including a GAO report and federal policy coordination, which became S.2126, the Representative Medicare Promotion Act. Also worked with White House on "Grand Challenge."
Agencies Lobbied
U.S. House of Representatives U.S. Senate Office of Science & Technology Policy (OSTP),
4th Quarter, 2013
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on Jan. 10, 2014.
Original Filing: 300612515.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Lobbied in support of legislation that will establish the national strategy, including a GAO report and federal policy coordination.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Office of Science & Technology Policy (OSTP),
3rd Quarter, 2013
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on Oct. 10, 2013.
Original Filing: 300592352.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Lobbied in support of legislation that will establish the national strategy, including a GAO report and federal policy coordination.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Office of Science & Technology Policy (OSTP),
2nd Quarter, 2013
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on July 12, 2013.
Original Filing: 300571433.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Lobbied in support of legislation that will establish the national strategy, including a GAO report and federal policy coordination.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Office of Science & Technology Policy (OSTP),
1st Quarter, 2013
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on April 10, 2013.
Original Filing: 300548153.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Lobbied in support of legislation that will establish the national strategy, including a GAO report and federal policy coordination.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Office of Science & Technology Policy (OSTP),
4th Quarter, 2012
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on Jan. 9, 2013.
Original Filing: 300526774.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied for FDA and NIH appropriation increase to prevent sequestration of funds.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
3rd Quarter, 2012
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on Oct. 8, 2012.
Original Filing: 300504330.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in HR 5651 & S. 3187 Patient Centered Outcomes Research Institute (PCORI). Lobbied for FDA appropriation increase. FDAappropriations eventually included in HR 2112 and S. 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. Lobbied for accelerated approval of regenerative medicine products for serious or life threatening conditions. These became part of HR 5651 the FDA Reform Act of 2012 and S. 3187 the FDA Safety and Innoviation Act. Reimbursement policies for regenerative medicine prodcuts; comparative effectiveness research studies related to regenerative medicine products. Drafted and submitted comments on proposed "methodology report" regarding comparative effectiveness research from the Patient Centered Outcome Research Institute.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS),
2nd Quarter, 2012
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on July 11, 2012.
Original Filing: 300482211.xml
Lobbying Issues
Advocate for creation of national strategy for regenerative medicine. Met with OSTP officals regarding same; Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in PDUFA reauthorization Energy & Commerce Committee draft legislation. Lobbied for FDA appropriation increase. FDAappropriations eventually included in HR 2112 and S. 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. Lobbied for accelerated approval of regenerative medicine products for serious or life threatening conditions. These became part of HR 5651 and FDA Reform Act of 2012 and S. 3187 the FDA Safety and Innoviation Act. Reimbursement policies for regenerative medicine prodcuts; comparative effectiveness research studies related to regenerative medicine products.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH) Office of Science & Technology Policy (OSTP) Centers For Medicare and Medicaid Services (CMS) Agency for Health Care Policy & Research
1st Quarter, 2012
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on April 3, 2012.
Original Filing: 300457484.xml
Lobbying Issues
Advocate for creation of federal coordinating entity for regenerative medicine. Met with NIH officals regarding same; Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in PDUFA reauthorization Energy & Commerce Committee draft legislation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH),
4th Quarter, 2011
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on Jan. 3, 2012.
Original Filing: 300434183.xml
Lobbying Issues
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with FDA officials about same. Work with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH) Natl Institute of Standards & Technology (NIST)
Lobbying Issues
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards for regenerative medicine. Support language in HR 2112 "Consolidated & Further Continuing Appropriations Act, 2012"
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institute of Standards & Technology (NIST)
Lobbying Issues
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2011
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on Oct. 11, 2011.
Original Filing: 300412032.xml
Lobbying Issues
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Work with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH) Natl Institute of Standards & Technology (NIST)
Lobbying Issues
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards for regenerative medicine.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institute of Standards & Technology (NIST)
Lobbying Issues
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Work with NIST officials on standards for reginerative medicine products. Advocate for assessment of federal regenerative medicine activities.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH) Natl Institute of Standards & Technology (NIST)
2nd Quarter, 2011
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on July 11, 2011.
Original Filing: 300387380.xml
Lobbying Issues
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH) Natl Institute of Standards & Technology (NIST)
Lobbying Issues
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institute of Standards & Technology (NIST)
Lobbying Issues
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Met with NIST officials on standards for reginerative medicine products. Advocate for assessment of federal regenerative medicine activities.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH) Natl Institute of Standards & Technology (NIST)
1st Quarter, 2011
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $80,000. The report was filed on April 6, 2011.
Original Filing: 300360471.xml
Lobbying Issues
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with NIST to explore collaborations re: manfacturing standards; Draft legislation to support regenerative medicine research
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH) Natl Institute of Standards & Technology (NIST)
Lobbying Issues
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institute of Standards & Technology (NIST)
Lobbying Issues
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Work with NIST on standards for reginerative medicine products. Advocate for assessment of federal regenerative medicine activities. Draft legislation to support regenerative medicine research and development.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH) Natl Institute of Standards & Technology (NIST)
4th Quarter, 2010
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $60,000. The report was filed on Jan. 3, 2011.
Original Filing: 300334728.xml
Lobbying Issues
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Lobby in support of HR 6173. Advocate for new/modified regulations re: aprroval of regenerative medicine products. The Regenerative Medicine Promotion Act of 2010. Met with NIST to explore collaborations re: product standards
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH) Natl Institute of Standards & Technology (NIST)
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Work with NIST on standards for reginerative medicine products.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH) Natl Institute of Standards & Technology (NIST)
3rd Quarter, 2010
In Q3, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $60,000. The report was filed on Oct. 6, 2010.
Original Filing: 300309166.xml
Lobbying Issues
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Draft and lobby in support of legislation that contains these provisions. Advocate for new/modified regulations re: aprroval of regenerative medicine products
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH)
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH)
2nd Quarter, 2010
In Q2, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $60,000. The report was filed on June 28, 2010.
Original Filing: 300281288.xml
Lobbying Issues
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Draft legislation that contains these provisions. Advocate for new/modified regulations re: aprroval of regenerative medicine products
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH)
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Natl Institutes of Health (NIH)
1st Quarter, 2010
In Q1, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $60,000. The report was filed on March 29, 2010.
Original Filing: 300253749.xml
Lobbying Issues
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Draft legislation that contains these provisions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Budget/Appropriations Science/Technology
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2009
In Q4, HOLLAND & KNIGHT LLP lobbied for Alliance for Regenerative Medicine , earning $60,000. The report was filed on Jan. 5, 2010.
Original Filing: 300227422.xml
Lobbying Issues
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs Science/Technology
4th Quarter, 2009
Holland & Knight LLP filed a lobbying registration on Nov. 4, 2009 to represent ALLIANCE FOR REGENERATIVE MEDICINE, effective Oct. 1, 2009.
Original Filing: 300224068.xml
Issue(s) they said they’d lobby about: Advocate for funding for regenerative medicine companies; Advocate for NIH funding. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate